Defining PSA Nadir After Definitive Therapy in Prostate Cancer
Brian Helfand, MD, PhD, describes the ways in which the PSA nadir can be defined after definitive therapy and the implications of the definition used for patients with prostate cancer.
Managing Prostate Cancer Surgical Patients during the COVID-19 Pandemic: A Brief Report of the Duke Cancer Institute’s Initial Experience
Experts from the Duke Cancer Institute outline their current approach to stratifying surgical management of patients with prostate cancer.